Bullish Insider Buying Activity Surfacing Among These Names In Real Estate, Healthcare

MannKind (MNKD)MannKind is a developmental drug company focused predominately on products relieving diabetes, most notably its AFREZZA product in late-stage clinical trials. The company has essentially no revenue (a miniscule $35,000 the past twelve months) while sustaining a loss in net income of $169 million over the same time-frame. Nonetheless, this speculative company, like Opko mentioned above, has a very large ownership stake by its Chairman and CEO, in the case of MannKind his name is Alfred Mann. Moreover, recently on December 20 2012, he bought a massive 40 million shares at $2.59 showing that he continues to believe the stock has more upside ahead.

http://seekingalpha.com/article/1345261-bullish-insider-buying-activity-surfacing-among-these-names-in-real-estate-healthcare?source=google_news